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SMA-MAP: A Plasma Protein Panel for Spinal Muscular
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Abstract
Objectives: Spinal Muscular Atrophy (SMA) presents challenges in (i) monitoring disease activity and predicting progression,
(ii) designing trials that allow rapid assessment of candidate therapies, and (iii) understanding molecular causes and
consequences of the disease. Validated biomarkers of SMA motor and non-motor function would offer utility in addressing
these challenges. Our objectives were (i) to discover additional markers from the Biomarkers for SMA (BforSMA) study using
an immunoassay platform, and (ii) to validate the putative biomarkers in an independent cohort of SMA patients collected
from a multi-site natural history study (NHS).
Methods: BforSMA study plasma samples (N = 129) were analyzed by immunoassay to identify new analytes correlating to
SMA motor function. These immunoassays included the strongest candidate biomarkers identified previously by
chromatography. We selected 35 biomarkers to validate in an independent cohort SMA type 1, 2, and 3 samples (N = 158)
from an SMA NHS. The putative biomarkers were tested for association to multiple motor scales and to pulmonary function,
neurophysiology, strength, and quality of life measures. We implemented a Tobit model to predict SMA motor function
scores.
Results: 12 of the 35 putative SMA biomarkers were significantly associated (p,0.05) with motor function, with a 13th
analyte being nearly significant. Several other analytes associated with non-motor SMA outcome measures. From these 35
biomarkers, 27 analytes were selected for inclusion in a commercial panel (SMA-MAP) for association with motor and other
functional measures.
Conclusions: Discovery and validation using independent cohorts yielded a set of SMA biomarkers significantly associated
with motor function and other measures of SMA disease activity. A commercial SMA-MAP biomarker panel was generated
for further testing in other SMA collections and interventional trials. Future work includes evaluating the panel in other
neuromuscular diseases, for pharmacodynamic responsiveness to experimental SMA therapies, and for predicting functional
changes over time in SMA patients.
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Development of non-SMN molecular biomarkers remains an area
for opportunity for SMA, and the recent BforSMA study was a
major advance in the discovery of new biomarkers for this disease
[25,26].
A biomarker panel that regresses to motor function scales likes
the HFMS, MHFMS, or HFMSE has several possible uses in preclinical and clinical studies. Performing the motor score assessment
causes fatigue in the patient; differences in effort and differences in
the encouragement given the patient by the assessor cause
variation in the motor score unrelated to changes in clinical
status. A biomarker panel may be a more reproducible measure of
disease status than the actual motor score, and may reduce the
fatigue and discomfort in the patient, and be less vulnerable to
inadvertent unblinding. By providing a more reproducible
measure of clinical status, the biomarker panel may provide more
reproducible measures of response to drug, potentially decreasing
sample size and duration of trials. The biomarkers found in the
human studies have analogs in animals, and these may be useful
pre-clinical studies and animal models of SMA.
Here we describe the discovery and validation of candidate
SMA blood biomarkers using both chromatographic and immunoassays, in two different SMA patient populations from the
BforSMA study and an SMA natural history study, which
produced a validated 27 analyte panel (SMA-MAP) [15]. Unless
otherwise stated, the analyses included types 1, 2, and 3 patients.

Introduction
Spinal Muscular Atrophy (SMA) is a rare genetic neuromuscular disease caused by the loss of the Survival Motor Neuron 1 gene
(SMN1). The depletion of the SMN protein in cells causes death of
alpha motor neurons, resulting in extreme weakness in proximal
muscles, particularly those required for breathing and posture.
The disease largely manifests in children with a continuum of
severity and developmental onset in which the most severely
affected (type 1) have symptoms before 6 months of age and are
unable to sit independently and often die within a few years of
birth, moderate disease patients (type 2) have symptoms by 18
months and are unable to walk independently, and patients with
milder forms (type 3) have onset after 18 months and are able to
walk but may lose the capacity to ambulate over time. SMA is the
epitome of a disease with high unmet medical need, as 1) there is
no effective treatment, 2) the most severely affected patients
succumb to respiratory failure, and 3) all patients experience
significant progressive functional decline and morbidity due to
extreme muscle weakness and atrophy.
However, there has been much progress in the development of
new SMA therapeutics and in the understanding of the biology of
the disease and SMN. New drugs being expressly developed for
SMA and similar diseases include ISIS-SMNRx (Isis Pharmaceuticals), Olesoxime (Trophos), and RG3039 (Repligen), with a
number of other programs in preclinical development [1]. As new
drugs advance through the clinic, outcome measures and
biomarkers will be utilized and validated by the SMA research
community. Several clinical studies using existing nervous system
or other drugs have been conducted in SMA including albuterol,
gabapentin, phenyl butyrate, riluzole, and valproic acid [2–9].
While none of the drugs have yet produced robust positive effects
in larger or well-controlled clinical trials, the field gained critical
expertise in the execution of trials, testing of study designs,
coordinating clinical networks and building and validating
outcome measures and also biomarkers. Several motor function
scales (including SMA-specific measures like the Hammersmith
Motor Function Scale or HFMS), quality of life scales (PedsQL
neuromuscular module, respiratory measures, strength tests, and
several putative biomarkers for SMN transcript and protein as well
as other outcome measures have already been piloted in these
intervention studies and in natural history studies and are ready
for use and validation in new drug trials [10–22].
However, new SMA biomarker investigation is an emerging
area of research, and prior efforts included exploring volumetric
MRI imaging and electrical impedance myography [23,24].
PLOS ONE | www.plosone.org

Results
Discovery Phase: BforSMA
The overall flow of SMA plasma protein biomarker candidates
from the discovery phase through validation and their inclusion in
the final SMA-MAP is depicted in Figure 1. The discovery phase
yielded 35 putative SMA biomarkers selected to progress into the
validation phase. We first re-examined the plasma proteomic data
from the BforSMA study, to identify the best proteins for building
new immunoassays [26]. Specifically, previously published data on
the intensity ratios for the protein analytes (available at
neuinfo.org/smabiomarkers and derived from multidimensional
liquid chromatography combined with isobaric tag for relative and
absolute quantitation or iTRAQ, Table S1) were analyzed against
MHFMS for each individual subject using univariate regression
[26]. We replicated the initial mathematical analysis excluding
non-SMA subjects, and found 84 markers associated with
MHFMS (Table 1), with considerable overlap to the prior analysis
that identified 97 analytes. A notable difference was the loss of
SPP1 as a top motor score regressor in the second analysis. New
2
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Figure 1. SMA plasma biomarker discovery campaign and confirmation schematic. Analyte markers were identified in different discovery
campaigns in two platforms. BforSMA samples were screened in LC/MS using iTRAQ technology, generating 84 markers that regressed with SMA
motor function (MHFMS). Samples from the same study were screened in commercially available Luminex panels, yielding an additional 64 markers
that regressed to motor function. There were 14 markers in the MAP panels that were hits in the LC/MS campaign, and 11 of these were repeat hits.
New Luminex assays were created to represent the top 8 analytes from the LC/MS analysis. Filtering was performed by evaluation of statistical
strength and assay performance, and 35 top analytes were selected for further MAP testing in a new sample set from the PNCRN natural history
study. An additional 91 analytes were present in the panels for testing, allowing discovery based on non-motor outcome data that was collected in
the PNCRN study. 13 analytes were repeat motor regressors, while 15 were new non-motor analytes. A total of 27 analytes were selected for inclusion
to the final SMA-MAP panel, which was validated for reproducibility using unthawed samples from BforSMA.
doi:10.1371/journal.pone.0060113.g001

We selected 35 biomarkers associated with one or more
dependent variables based on statistical significance, importance
in random forest models, and non-statistical criteria such as assay
performance, distribution of values near or below the lower limits
of quantitation or detection and known biological relationships
(Table S2). Other criteria for selection included performance of
assays and long-term availability of reagents. This pilot 35
biomarker set included the 8 biomarkers chosen from the LC/
MS campaign for new assay development. The 35 biomarkers
chosen for validation were present on pre-existing multiplexes that
included an additional 91 proteins, so these additional analytes
were also examined.

Luminex assays were created for 8 candidate biomarkers that were
among the strongest motor regressors with available reagents:
CD93, CDH13, COMP, DPP4, LUM, PEPD, THBS4, and
TNXB.
Next, we used the BforSMA samples to probe for new motor
function markers in ready-made Luminex panels in multiplex
format (DiscoveryMAP v1.0H and OncologyMAP v1.0H by
Myriad RBM, a total of 233 analytes). Analysis of BforSMA
samples in DiscoveryMAP v1.0H and OncologyMAP v1.0H
identified 51 and 13 new motor function associated biomarker
candidates respectively (Table 1). Plasma concentrations for each
protein of interest were analyzed for regression to the MHFMS for
each subject. 14 analytes present in the MAPs were identified as
markers with statistically significant association with motor
function in the LC/MS study –11 of these also significantly
associated with motor function in the MAP analysis (Table 2). Of
the analytes that could not be reproduced as motor regressors,
IGFBP5 and SHBG gave marginally significant LC/MS p-values
of 0.045 and 0.038. HP also did not repeat, possibly due to sample
processing differences between the LC/MS and immunoassay
platforms.
We examined the association of the biomarkers with MHFMS
scores, SMN2 copy number, SMN protein levels, and quantity of
SMN2 full length, SMN full length, SMN7 delta, and total SMN
transcripts. The analyses included univariate methods and
multivariate regression methods (linear regression, lasso, stepwise
regression, and random forest).
PLOS ONE | www.plosone.org

Validation Phase: PNCR Natural History Study
The 35 putative SMA biomarkers from the discovery phase
were evaluated in an independent cohort of SMA patients: a
natural history study (NHS) by the Pediatric Neuromuscular
Clinical Research (PNCR) network that included subjects with
more severe disease and from a broader range of ages than
BforSMA (0.25–45 years, versus 2–12 years) [15,22].
We tested the 35 analytes for relationships with motor function
measures (HFMS). In linear regression analyses of the 35
candidates, we found 12 significantly associated (p,0.05) with
motor function and a 13th with a p-value of 0.058 (Table 3). The
set of 13 top analytes includes APCS, AXL, CD93, CDH13,
CHI3L1, COMP, DPP4, LEP, LUM, MB, PEPD, SPP1, and
THBS4. These 13 analytes became candidates for inclusion in the
3
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Table 1. SMA plasma protein marker that regress to motor function (MHFMS).

BforSMA LC/MS Markers

Correlation to MHFMS

Protein

Name

R-value

p-value

CILP2

Cartilage intermediate layer protein 2

0.76

,0.001

TNXB

Tenascin XB

0.72

,0.001

CLEC3B

Ctype lectin domain family 3, member B (tetranectin)

0.65

,0.001

TNXB

Tenascin XB

0.60

,0.001

ADAMTSL4

ADAMTSlike 4

0.56

,0.001

THBS4

Thrombospondin 4

0.52

,0.001

COMP

Cartilage oligomeric matrix protein

0.52

,0.001

CRTAC1

Cartilage acidic protein 1

0.48

,0.001

F13B

Coagulation factor XIII, B polypeptide

0.46

,0.001

PEPD

Peptidase D

0.44

,0.001

LUM

Lumican

0.43

,0.001

CD93

Complement component 1, q subcomponent, receptor 1

0.42

,0.001

Mixed complement C2/B

20.41

,0.001

APCS

Amyloid P component, serum

20.39

,0.001

VTN

Vitronectin

20.38

,0.001

DPP4

Dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein 2)

0.38

,0.001

CRP

C-reactive protein, pentraxinrelated

20.37

,0.001

HBB

Hemoglobin beta

20.37

,0.001

GSN

Gelsolin

0.37

,0.001

NCAM1

Neural cell adhesion molecule 1

0.35

,0.001

CFI

I factor (complement)

20.35

,0.001

APOA4

Apolipoprotein AIV

0.35

,0.001

VTN

Vitronectin

20.35

,0.001

F13A1

Coagulation factor XIII, A1 polypeptide

0.35

,0.001

INHBC

Inhibin, beta C

20.34

,0.001
0.001

RPS27A

Ubiquitin and ribosomal protein S27a precursor

20.33

CDH13

Cadherin 13, Hcadherin (heart)

0.33

0.001

mixed Complement C2/B

20.33

0.001

C2

Complement component 2

20.33

0.001

CP

Ceruloplasmin (ferroxidase)

20.32

0.001
0.001

HBA

Hemoglobin subunit alpha

20.31

QSOX1

Quiescin Q6

0.31

0.001

LRG1

Leucine-rich alpha2-glycoprotein 1

20.30

0.002

C9

Complement component 9

20.30

0.002

SERPINA10

Serpin peptidase inhibitor, clade A (alpha1 antiproteinase, antitrypsin), member 10

20.30

0.002

ALP

Alkaline phosphatase, liver/bone/kidney

0.29

0.003

mixed fc-gamma receptor III-A/B

0.29

0.003
0.003

PROC

Protein C (inactivator of coagulation factors Va and VIIIa)

20.28

VCAM1

Vascular cell adhesion molecule 1

0.28

0.003

GAPDH

Glyceraldehyde-3-phosphate dehydrogenase

20.28

0.004

OMD

Osteomodulin

0.27

0.006

IGKVD41

Immunoglobulin kappa variable 41

20.27

0.006

IGFBP6

Insulinlike growth factor binding protein 6

0.26

0.007

PTPRG

Protein tyrosine phosphatase, receptor type, G

0.26

0.008

S100A9

S100 calcium binding protein A9 (calgranulin B)

20.26

0.008

VNN1

Vanin 1

20.26

0.008

SERPIND

Serpin peptidase inhibitor, clade D (heparin cofactor), member 1

20.26

0.009

CA1

Carbonic anhydrase I

20.25

0.009

PLOS ONE | www.plosone.org
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Table 1. Cont.

BforSMA LC/MS Markers

Correlation to MHFMS

Protein

Name

R-value

p-value

CTSD

Cathepsin D (lysosomal aspartyl peptidase)

20.25

0.01

HP

Haptoglobin

20.25

0.011

SELENBP1

Selenium binding protein 1

20.25

0.011

ORM2

Orosomucoid 2

20.25

0.012

PRDX2

Peroxiredoxin 2

20.25

0.012

AOC3

Amine oxidase, copper containing 3 (vascular adhesion protein 1)

0.25

0.012

Collagen, type VI, alpha 3

0.24

0.012

Unidentified protein

20.24

0.013

COL6A3

PZP

Pregnancyzone protein

20.24

0.013

COL6A1

Collagen, type VI, alpha 1

0.24

0.014

PARK7

Parkinson disease (autosomal recessive, early onset) 7

20.24

0.014

THBS1

Thrombospondin 1

20.24

0.015

CAT

Catalase

20.24

0.016

LCP1

Lymphocyte cytosolic protein 1 (Lplastin)

0.23

0.018

AFM

Afamin

20.23

0.021

HPR

Haptoglobinrelated protein

20.22

0.021

SELL1

Selectin L (lymphocyte adhesion molecule 1)

0.22

0.023

ENG

Endoglin

0.22

0.023

PFN1

Profilin 1

20.22

0.026

PI16

Peptidase inhibitor 16

0.22

0.026

SERPINA6

Serpin peptidase inhibitor, clade A (alpha1 antiproteinase, antitrypsin), member 6

0.21

0.028

Unidentified protein

20.21

0.03

F9

Coagulation factor IX

20.21

0.03

PROCR

Protein C receptor, endothelial

0.21

0.031

ORM1

Orosomucoid 1

20.21

0.031

NEO1

Neogenin homolog 1

0.21

0.032

MMRN2

Multimerin 2

0.21

0.033

LGB

Beta-lactoglobulin

20.21

0.034

CNTN4

Contactin 4

0.21

0.035

SHBG

Sex hormonebinding globulin

0.20

0.038

CA2

Carbonic anhydrase II

20.20

0.043
0.045

IGFBP5

Insulinlike growth factor binding protein 5

20.20

PLTP

Phospholipid transfer protein

0.20

0.046

FGA

Fibrinogen alpha chain

20.20

0.046

Unidentified protein

0.19

0.05

Tropomyosin 4

20.19

0.05

TPM4

DiscoveryMAP Markers

Correlation to MHFMS

Protein

Name

R-value

p-value

MB

Myoglobin

0.57

,0.001

SPP1

Osteopontin

0.54

,0.001

AXL

AXL receptor tyrosine kinase

0.44

,0.001

APSC

Amyloid P component, serum

20.42

,0.001

CRP

C-reactive protein, pentraxinrelated

20.41

,0.001

CCL22

Chemokine (C-C motif) ligand 22 (macrophage derived chemokine)

20.41

,0.001

THBD

Thrombomodulin

0.40

,0.001

CALCA

Calcitonin

20.40

,0.001

LEP

Leptin

20.40

,0.001

PLOS ONE | www.plosone.org
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Table 1. Cont.

BforSMA LC/MS Markers

Correlation to MHFMS

Protein

Name

R-value

p-value

NPPB

Brain natriuretic peptide b

0.37

,0.001

MMP2

Matrix Metalloproteinase 2

0.37

,0.001

CK

Creatine kinase muscle/bone

0.36

,0.001

ACE

Angiotensin converting enzyme

0.36

,0.001

FAPB3

Fatty acid binding protein (heart)

0.35

,0.001

CD40

CD40 Ligand

20.34

,0.001

MIF

Macrophage Migration Inhibitory Factor

20.34

,0.001

ANGPT2

Angiopoietin 2

20.33

,0.001

AHSG

Alpha-2-HS-glycoprotein (fetuin A)

20.33

0.001

CFH

Complement factor H

20.33

0.001

IL8

Interleukin 8

20.32

0.001

C3

Complement component 3

20.32

0.001

PPY

Pancreatic polypeptide

0.31

0.001

VEGFA

Vascular endothelial growth factor

20.30

0.002
0.002

TF

Transferrin

20.29

PGF

Placental growth factor

0.29

0.002

EGF

Epidermal growth factor

20.29

0.002

GSTA1

Glutathione S transferase alpha

20.29

0.002

SOD1

Superoxide dismutase 1

20.29

0.003

VCAM1

Vascular cell adhesion molecule 1

0.28

0.003

PAI1

Plasminogen activator inhibitor 1

20.28

0.004

CSF1

Macrophage colony stimulating factor 1

0.28

0.004

S100A12

S100 Protein A12

20.28

0.004

VTN

Vitronectin

20.27

0.004

FASLG

Fas ligand

0.26

0.006

A1M

Alpha-1-microglobulin

20.26

0.007

AST

Astartate transaminase

0.25

0.009

ACCT

Alpha-1-antichymotrypsin

20.25

0.01

CCL3

Chemokine (C-C motif) ligand 3 (Macrophage Inflammatory Protein 1 beta)

20.25

0.011

SORT1

Sortilin

20.24

0.013

TBG

Thyroxine binding globulin

20.24

0.014

APOA1

Apolipoprotein A1

0.24

0.015

MPO

Myeloperoxidase

20.23

0.016

B2M

Beta 2 microglobulin

0.23

0.016

EPO

Erythropoietin

20.23

0.017

MMP10

Matrix Metalloproteinase 10

20.23

0.02

PROS1

Vitamin K Dependent Protein S

20.22

0.023

MMP7

Matrix Metalloproteinase 7

20.22

0.025

AGER

Advanced glycosylation end products receptor

0.21

0.029

IL18

Interleukin 18

0.21

0.033

CCL11

Chemokine C-C motif ligand 11

20.21

0.034

IGA

Immunoglobulin A

20.20

0.035

C peptide

Proinsulin C Peptide

20.20

0.041

A2M

Alpha-2-macroglobulin

20.20

0.041

PDGF BB

Platelet Derived Growth Factor

20.20

0.042

CCL16

Chemokine C-C motif ligand 16

20.19

0.047

IL1A

Interleukin 1 alpha

0.19

0.049

APOA4

Apolipoprotein A4

0.19

0.049
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Table 1. Cont.

BforSMA LC/MS Markers

Correlation to MHFMS

Protein

Name

R-value

p-value

MMP9

Matrix metalloproteinase 9

20.19

0.05

OncologyMAP Markers

Correlation to MHFMS

Protein

Name

R-value

p-value

SPP1

Osteopontin

0.53

,0.001

CLEC3B

Ctype lectin domain family 3, member B (tetranectin)

0.51

,0.001

IGFBP6

Insulin-like growth factor binding protein 6

0.48

,0.001

FABP4

Fatty acid binding protein (adipocyte)

20.45

,0.001

CHI3L1

Chitinase 3-like 1 (YKL-40)

20.41

,0.001

LEP

Leptin

20.39

,0.001

CTSD

Cathepsin D

20.33

0.001

MST1

Macrophage stimulating 1 (hepatocyte growth factor-like)

20.33

0.001

MIF

Macrophage migration inhibitory factor

20.32

0.001

S100A4

S100 calcium binding protein A4

20.32

0.001
0.001

GLO1

Glyoxalase 1 (lactoylglutathione lyase)

20.32

ENG

Endoglin

0.30

0.001

FTL1

Fms-related tyrosine kinase 1 (vascular endothelial growth factor receptor)

20.30

0.002

ERBB2

Human epidermal growth factor receptor 2 (HER2)

20.28

0.003

NDKB

Nucleoside phosphatase kinase isoform B

20.28

0.004

PRDX-4

Peroxiredoxin 4

20.25

0.01

PLAUR

Plasminogen activator, urokinase receptor

20.24

0.015

IL6R

Interleukin 6 receptor

0.23

0.02

CCL24

Chemokine (C-C motif) ligand 24 (eotaxin 2)

20.21

0.034

GSN

Gelsolin

0.20

0.038

PSAT1

Phosphoserine aminotransferase 1

20.20

0.039

TGFB1

Transforming growth factor beta 1

20.19

0.049

Markers that regressed to MHFMS SMA motor scores from the BforSMA study are listed by each analysis with their R-values and p–values. TNXB appears twice due to
the positive regression with two unique isoforms.
doi:10.1371/journal.pone.0060113.t001

less strong and also less numerous than those for the motor
function regressors (Table 1, Table S4). One notable exception to
this observation was pulmonary function, as adjusted R2 for FVC
was as high as 0.62. Overall this may lend confidence to our
approach in using motor function, as motoric changes specifically
are what typify SMA disease progression.

Tobit regression model to predict HFMS, described below [27].
These 13 showed similar regression results in analyses of other
motor function endpoints (HFMSE, GMFM, CHOP-TOSS and
highest motor function). Neither weight, height, age at clinic visit,
age at enrollment, nor SMN2 transcript or protein levels, was
found to be important clinical covariates to the regression results.
However age of onset was found to be an important clinical
covariate and was included in the Tobit models to predict motor
scores described below. The 13 biomarkers were also combined in
a logistic regression model to discriminate among SMA types using
a receiver-operator curve (ROC) analysis; AUCs for classification
of SMA type ranged from 0.94 to 1 (Figure 2).
The association of the 35 biomarkers with non-motor SMA
outcome measures was also examined: pulmonary function (FVC),
electrophysiology (CMAP and MUNE), quality of life (PedQL),
and myometric strength measures of elbow flexion (MyoEF),
elbow extension (MyoKE), and knee flexion (MyoKF). The top 13
motor function biomarkers were in general poorly associated with
the non-motor outcomes with R2-values ranging from 0 to 0.36.
However, other analytes were associated with non-motor outcomes; these were either previously identified as motor function
markers in BforSMA, or were altogether novel markers (Table 4).
In general, analyte relationships to the non-motor outcomes were
PLOS ONE | www.plosone.org

Biomarker Panel: SMA-MAP
27 analytes were selected for inclusion into a new biomarker
panel, called SMA-MAP (Table 5). The 13 analytes that regressed
to motor outcomes of SMA in both the BforSMA and PNCR
NHS studies were included. An additional 12 SMA-MAP analytes
(AHSG, APOB, CCL2, CFH, CLEC3B, CRP, CTSD, ENG,
ERBB2, FBLN, IFBP6, PGF, TNXB) were motor regressors from
the BforSMA analysis and/or related to non-motor outcomes.
Lastly, IGF1 was included due to the reported disruption of the
IGF pathway in SMA models and human muscle as well as
interest in IGF1 therapy for SMA [28–32]. The SMA-MAP panels
were assembled to minimize sample volume requirements,
requiring only 100 mL per sample for analysis, and met multiplex
assay validation acceptance criteria. SMA-MAP analytes were
verified in a multiplex, and tested for the fundamental assay
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Table 2. BforSMA LC/MS and MAP Repeat Hit Rankings.

LC/MS

DiscoveryMAP v1.0H

OncologyMAP v1.0H

APCS

14

4

N/A

APOA4

22

57

N/A

Table 3. Top 13 SMA motor function regressors are markers
in two SMA populations.

Correlation to MHFMS
PNCR NHS values

BforSMA values

CTSD

49

N/A

7

Protein

R-value

p-value

R-value

p-value

CRP

17

5

N/A

COMP

0.526

,0.001

0.519

,0.001

ENG

66

N/A

12

AXL

0.5

,0.001

0.414

,0.001

GSN

19

N/A

20

CD93

0.487

,0.001

0.416

,0.001

HP

50

N/A

89 (non-hit)

PEPD

0.485

,0.001

0.444

,0.001

IGFBP6

43

N/A

3

THBS4

0.444

,0.001

0.523

,0.001

SPP1

*

2

N/A

LUM

0.423

,0.001

0.427

,0.001

THBS1

60

103 (non-hit)

N/A

MB

0.401

0.001

0.573

,0.001

VCAM1

39

29

N/A

DPP4

0.397

0.001

0.375

,0.001

VTN

15,23

33

N/A

SPP1

0.382

0.002

0.536

,0.001

SHBG

78

75 (non-hit)

N/A

CHI3L1

20.314

0.01

20.426

,0.001

IGFBP5

80

N/A

50 (non-hit)

CDH13

0.255

0.039

0.329

0.001

APCS

20.252

0.041

20.422

,0.001

LEP

20.235

0.058

20.384

,0.001

Analytes that were motor function regressor hits in the LC/MS campaign that
were represented on the MAP panels were ranked side-by-side. The majority of
markers were repeat hits, while some did not repeat (non-hit).
*indicates that marker SPP1 was a strong hit analyte in the original analysis of
BforSMA hits using different statistical methods. VTN appears twice in the LC/
MS analysis due to the presence of multiple hit isoforms.
doi:10.1371/journal.pone.0060113.t002

The top 13 list was compiled based on significant regression to HFMS and other
SMA motor outcome measures in the PNCRN natural history study sampleset.
The pilot panel of markers tested included 35 top motor analytes identified via
the BforSMA study and these 13 analytes represent robust repeat markers in a
distinct SMA population.
doi:10.1371/journal.pone.0060113.t003

parameters of lowest detectable dose, precision, cross-reactivity,
linearity, spike-recovery, dynamic range, matrix interferences,
freeze-thaw stability and bench-top stability (Table S3).
Unthawed BforSMA aliquots were re-analyzed using SMAMAP to compare its analyte values to the initial values generated
from DiscoveryMAP v1.0H, OncologyMAP v1.0H, and the new
assays created for the 8 LC/MC hit analytes.

selected the final model by testing all possible subsets of the top 13
analytes, with data from SMA type 1, 2, and 3 subjects from the
BforSMA study. All 13 analytes were entered as candidates in the
models. Performance of the models was compared using adjusted
Pearson R2 values between actual and predicted motor scores
calculated on bootstrap (out-of-bag) samples. Six analytes (APCS,
COMP, DPP4, LEP, MB, and THBS4) produced a model with
the highest bootstrap out-of-bag correlations of predicted with
actual motor scores. Many alternative models with different
subsets of the analytes gave similar our-of-bag performance. The
correlation between actual and predicted BforSMA scores with the
6 analytes was R = 0.89 for scores censored between 0–40 and
R = 0.86 for uncensored scores (Figure 3). Separate models were

Regression Model to Predict Motor Scores
We developed a Tobit regression model to predict MHFMS
scores using SMA-MAP biomarker values, based on the MHFMS
framework and age of onset information from BforSMA. As noted
above, age of onset was found to be an important clinical covariate
in the linear regression analyses for both BforSMA and the PNCR
NHS studies, and thus was included in the Tobit modeling. We

Figure 2. Classification of SMA types by the top 13 biomarker analytes Receiver-Operator curves. (ROCs) and (area under the curves
(AUCs) were generated for the top 13 markers to differentiate between SMA types within the PNCRN’s natural history study dataset. Both sensitivity
(True positive rate) and specificity (1-False positive rate) of the SMA type classifications were very high across several thresholds. A: Type 1 versus
Type 2 AUC was 0.98. B: Type 1 versus Type 3 AUC was 1. C: Type 3 versus Type 3 AUC was 0.94.
doi:10.1371/journal.pone.0060113.g002
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Table 4. SMA non-motor outcome regressors.

Table 4. Cont.

Outcome
Measure

Analyte

R-value

p-value

Outcome
Measure

CHOP-TOSS

ERBB2

0.597

0.002

MB

0.36

0.005

IL10

0.432

0.035

DPP4

0.321

0.012
0.012

FVC

CMAP

MYOEF

MYOKF

MYOKE

Analyte

R-value

p-value

IL18

0.422

0.04

FBLN1C

20.324

IGFBP1

0.41

0.046

APOB

20.32

0.013

GOT1

0.412

0.046

PGI

20.32

0.013

INS

20.405

0.049

MMP9

20.297

0.021

MB

0.52

0

ANG

20.292

0.024

TNFR2

0.432

0.001

THBS4

0.278

0.032

A2M

20.374

0.005

TNXB

20.276

0.033

CCL4

0.339

0.011

MSP

20.269

0.038

RSTN

0.328

0.013

CD93

0.264

0.042

TNFRI

0.33

0.013

FRTN

0.263

0.043

IGFBP5

20.323

0.015

FRTN

0.306

0.022

UPA

20.303

0.023

pINS

0.3

0.024

PQP

PQC

AXL

0.394

0.001

DPP4

0.297

0.012

ADIPOQ

20.294

0.013

CD93

0.456

0.001

AXL

0.273

0.042

FASLR

0.424

0.002

TIMP1

0.27

0.044

CLEC3B

0.367

0.007

FBLN1C

20.264

0.049

INS

0.27

0.05

IL10

0.264

0.049

DPP4

0.261

0.022

ADIPOQ

20.256

0.025

APOB

20.252

0.027

pINS

0.246

0.031

CCL4

20.245

0.032

LUM

0.244

0.033

PPY

0.238

0.037

IL12P40

20.236

0.039

MMP7

20.236

0.039

VWF

0.236

0.039

Several markers were identified in the PNCR NHS as regressing to the Children’s
Hospital of Philadelphia Test of Strength (CHOP-TOSS), pulmonary function
(best FVC), electrophysiology (CMAP and MUNE), strength as measured by knee
and elbow flexion and extension(log average MyoEF, MyoKE, MyoKF), parentreported and child-reported quality of life (PQP and PQC).
doi:10.1371/journal.pone.0060113.t004

created to predict scores within the 0–40 numeric range, and one
with uncensored scores. Coefficients for the motor score regression
model for the 6 SMA-MAP analytes and age of onset as well as an
Excel-based version of the predictive tool are available for
download (http://neuinfo.org/smabiomarkers/).

PEPD

0.226

0.048

Discussion

MB

0.455

,0.001

PEPD

0.385

0.002

pINS

0.298

0.018

The use of plasma protein biomarkers for cardiovascular disease
and cancer has been transformative in advancing new drug
development and improving care management. SMA could also
potentially benefit from new biomarkers, as several new drugs are
in or poised to enter clinical trials [1]. SMA is a rare pediatric
disease with significant unmet medical need, a heterogeneous
presentation and a disease course punctuated by irreversible events
(e.g. loss of the ability to walk). Thus it is vital to validate
biomarkers that could help shorten the length of drug trials,
stratify patient populations, and allow for smaller study sizes.
Molecular biomarkers are valuable complements to clinical SMA
motor outcome measures that are subject to age limitations and
motivation for performance [10]. Also, while several SMN-based
pharmacodynamic (PD) biomarkers for SMA exist, not all trials
will test SMN-upregulating drugs, and other non-SMN markers
would be needed [21,25,33]. In addition, not all therapeutic
interventions will be delivered systemically, and use of a biomarker
matrix like plasma that reflects proteins from a number of sites
may provide additional insights over measures based in blood cells
[33].

A2M

20.274

0.031

DPP4

0.274

0.031

pINS (total)

0.271

0.033

pINS

0.398

0.002

pINS (Total)

0.345

0.008

MB

0.311

0.017

INS

0.306

0.019

IGFBP1

20.27

0.038

PEPD

0.27

0.038

DPP4

0.261

0.046

COMP

0.259

0.047

COMP

0.421

0.001

LUM

0.41

0.001

TG

20.394

0.002

PEPD

0.38

0.003
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represented in panels. In the validation phase we tested PNCR
samples to confirm our results, choosing to delay selecting a small
number of analytes until further analysis. A large pilot panel of 126
analytes confirmed prior results with our top 35 motor markers.
Also we identified candidate markers for non-motor outcomes that
figure to be important secondary outcome measures for SMA trials
– all of which require confirmation in another patient collection
(Figure 1). While some of these candidate markers identified also
regressed to motor function, several others associated with nonmotor outcome measures like electrophysiology, muscle strength,
pulmonary function, and quality of life were novel. Data from all
phases of analysis were used to assemble a panel of 27 analytes,
filtering by strength of regression to motor function and other
outcome measures, and assay performance.
SMA-MAP complements established clinical outcome measures
and markers, and has novel advantages and benefits. The tool can
generate predicted motor scores based on the framework of the
MHFMS. Correlation values of predicted and actual motor scores
were relatively high, with adjusted R2-values values reaching 0.56
in multivariate modeling when age of onset was used as a covariate
(Table S4). The importance of age on the SMA biomarker
regression to clinical outcome measures echoes relationships
between age and SMN transcript in the BforSMA study and
disease duration and motor function reported by Tiziano et al.
[25,34]. While motor regression values were high for the SMAMAP motor analytes, imperfections in the correlations themselves
may be valuable, as actual motor scores from SMA children are
subject to motivation, while values from a biochemical panel are
more objective. Tobit model motor prediction can also range
below and above motor scale floor and ceiling values, allowing
prediction of motor function in type 1, 2 and 3 SMA patients
using the same tool [27]. Also, the SMA-MAP allows evaluation in
subjects who are younger than are usually testable in motor scales
(30 months) [10].
While the regression values of the panel analytes to motor
function are strong and top analytes were confirmed in different
cohorts, there are limiting aspects to our approach. One obvious
weakness is that SMA-MAP is based on plasma analytes whereas
SMA is a disease in which muscle and spinal motor neurons are
the most affected tissues and cells. Tissue samples (e.g. muscle
biopsies) were not collected in the BforSMA and thus no
relationships between neuromuscular disease-relevant tissues and
the SMA-MAP were assessed. It should be noted however, that
SMA patients and models have other non-neuromuscular disease
features as well, including potential metabolic syndromes [35,36].
Use of plasma could potentially be advantageous, as achieving
consistent and high-quality sampling with plasma is more
straightforward than with muscle – which has been shown to
generate markedly different biomarker signatures and denervation
patterns in SMA mice depending on sampling site [37,38].
Another notable deficit in the generation of SMA-MAP is that it
did not rely heavily on longitudinal sampling in its development.
The BforSMA study that generated samples for the majority of the
discovery process was a single-visit clinical study, while only
baseline and 12 month visits were assessed in the PNCR study.
There were only N = 55 PNCR study subjects represented at both
timepoints in the validation experiment – a number too small to
generate a meaningful statistical analysis. As a result, though these
biomarkers may classify SMA severity across a spectrum of motor
phenotypes, they are not classical biomarkers of progression. As
with any potential biomarker, these limitations will not be
remedied and their utility will not be expanded upon without
significant additional work by the greater research community.

Table 5. SMA-MAP analytes and their correlated outcomes.

Analyte

Correlated Outcome Measures

APOB

CMAP, Strength

APCS

Motor

ASHG

Motor, PD, CMAP, Strength

AXL

FVC, Motor, PD?, PQP

CCL2

PD?

CD93

Motor, MUNE, PQC, Strength

CFH

Motor

CDH13

Motor

CHI3L1

Motor

CLEC3B

Motor, PQC

COMP

Motor, MUNE, Strength

CRP

Motor, PD?

CTSD

Motor

DPP4

Motor, MUNE, PQP, Strength

ENG

Motor, PD?

ERBB2

CHOP-TOSS, Motor, PD?

FBLN1

FVC, Motor, PD?, Strength

IGF1

PD?

IGFBP6

Motor, PD?

LEP

Motor

LUM

CMAP, Motor, MUNE, PD? Strength

MB

FVC, Motor, Strength

PEPD

CMAP, Motor, MUNE, Strength

PGF

Motor, MUNE, PD?

SPP1

Motor

THBS4

Motor, MUNE, PD?

TNXB

Motor

CHOP-TOSS = Children’s Hospital of Philadelphia Test of Strength, FVC = forced
vital capacity, Motor = motor function scale (e.g. MHFMS, HFMS, HFMSE, GMFM),
PD = SMN pharmacodynamic measure, CMAP = compound motor action
potential, MUNE = motor unit number estimation, PQP = PedQL quality of life,
parent score, PQC = PedQL quality of life, child score, CHOP-TOSS = Children’s
Hospital of Philadelphia Test of Strength.
doi:10.1371/journal.pone.0060113.t005

Here we describe the development of a biomarker panel (SMAMAP) for plasma proteins in SMA patients associated primarily
with motor function and confirmed in multiple patient populations
from infancy to adulthood that can be used to help evaluate the
current neuromuscular status of patients. The work described here
advances the prior publication on candidate plasma protein
biomarkers discovered by mass-spectrometry proteomics in the
BforSMA study in a number of ways: by reanalyzing the LC/MS
results in the context of SMA patients only, validating a subset of
those analytes and identifying new putative markers in a different
platform, as well as confirming the strongest markers in a new
SMA cohort. The resulting SMA-MAP panel can accurately
classify SMA patients by type, generate predicted motor function
scores, and a subset may have relationships to pathways linked to
SMN or associate with non-motor outcome measures (Figure 4).
In the discovery phase with BforSMA samples analytes were
probed for relationships to SMA motor function. We employed
off-the-shelf biomarker panels from Myriad RBM that required
modest volumes of plasma to advance our analyses quickly, and
built new assays for the strongest LC/MS discovery hits not
PLOS ONE | www.plosone.org
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Figure 3. SMA-MAP motor function score prediction model. Using Tobit linear regression models SMA motor scores were predicted from
SMA-MAP analytes values with age of onset as a covariable. Pearson correlations between actual and predicted motor scores for the top 6
combinations from BforSMA were plotted. A: Graph of actual and predicted motor scores of a 6 analyte model uncensored model. Type 1 SMA
patients and ambulatory Type 3 subjects can be represented in the analysis and given a score below 0 or over 40 respectively. B: Graph of 6 analyte
motor scores using values censored between 0 and 40. Note that the Type 1 datapoints have been moved arbitrarily to the right to allow
visualization, and these points still represent values of 0.
doi:10.1371/journal.pone.0060113.g003

with proteins involved with promoting entry into the cell cycle and
stem cell proliferation, and that SMN is highest in mammalian
tissues with greater regenerative capacity [53–55].
Some top analytes (e.g. AXL, CLEC3B, COMP, ERBB2,
IGF1, PGF, SPP1) could be SMA PD markers of drug-induced
SMN changes. These markers and many others in the biomarker
candidate list (Table 1) are members of RTK/mTOR, STAT,
TGFB/SMAD/BMP or p21 pathways that have been published
in SMA cellular, invertebrate, and mouse models as modulators of
disease phenotype and SMN [28,29,56–60]. Some analytes
probed had been identified as possible SMA therapeutic targets
or biomarkers: CCL2, GLO1, IGF1, and PRL [28–31,61,62].
These potential PD markers require analysis in an SMNupregulating in vivo treatment paradigm.
Our unbiased biomarker identification plan raises uncertainties
about which markers are specific to SMA or are common to
secondary neuromuscular degeneration. Indeed, some SMA-MAP
analytes are themselves markers or members of biological
networks implicated for Amyotrophic Lateral Sclerosis (ALS),
Duchene Muscular Dystrophy (DMD) or other neurodegenerative
diseases: CCL2 and ENG for ALS, LUM and SPP1 for DMD,

Many SMA-MAP markers are pleiotropic connective tissue,
extracellular matrix, and growth factor pathway proteins that play
roles in neural development, injury, and maintenance [39,40].
While it is tantalizing to imagine these markers are signals to
similar processes in SMA, their relationship to underlying disease
biology is unclear. The top 13 markers are also biomarkers of
Ehlers-Danloss (TNX), and juvenile, osteo- and rheumatoid
arthritis, all of which have feature connective tissue damage and
abnormal mobility of joints. (CLEC3B, COMP, LUM, SPP1) [41–
44]. Aside from lowered bone fracture thresholds due to an
inability to bear weight, there is also some evidence that SMN
interacts with bone proteins [45,46]. Other markers like CDH13,
DPP4, IGF1, and LEP are involved in control of body
composition, growth, and insulin regulation, all of which are
either altered in SMA or being more actively explored [35,47–52].
Molecularly, this may be of some interest, as both severe growth
failure in some forms of primordial dwarfism and SMN deficiency
are associated with reductions in components and activity of the
minor spliceosome (Lotti 2012, He 2011). Lastly, many of these
markers have been identified in oncology studies. There are no
data on cancer in SMA, but there are reports that SMN interacts

Figure 4. Several types of biomarkers for SMA-MAP analytes. SMA biomarkers were identified for their regression to motor function and nonmotor outcome measures. The analytes have been confirmed and validated to different degrees and will require more validation in prospective,
longitudinal studies to determine their utility as biomarkers for disease progression and pharmacodynamic response.
doi:10.1371/journal.pone.0060113.g004
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and CRP, CTSD, and IGF1 for Parkinson’s and Alzheimer’s
[60,63–75]. While biomarkers specific to SMA could also help
shed light on disease biology and perhaps identify new therapeutic
targets, our goal was to identify and confirm biomarkers sensitive
to patient status regardless of specificity to SMA. We do
recommend more comprehensive pathway analyses be performed
on these biomarkers. These studies could include analysis of
disease-relevant SMA tissue, mouse model studies with drug
treatment, and also analysis of other disease control analysis with
plasma from other neuromuscular and neuropathic disorders.
These could include ALS, DMD, and congenital myotonic
dystrophies, particularly ones like Nemaline and Central Core
CMD that are similar to SMA in that they lack necrotic and
fibrotic muscle atrophy features. Indeed if the panel is not specific
to SMA and shows utility in other diseases, it will remain useful for
research for assessing disease stage in confirmed SMA cases.
There are also caveats and potential areas for further
investigation related to the statistical methods. In any situation
in which the number of analytes is relatively high compared to the
number of samples being analyzed, there is a risk of overestimating
the strength of statistical relationships. To mitigate this, we
modeled the association with 100 rounds of multivariate bootstrapping and represented the output in adjusted R-values, which
penalizes the number of variables in the models. The motor
prediction tool operates within the framework of the MHFMS or
the HFMS, but could be modified for other motor scales like the
GMFM or HFMSE. The motor prediction tool itself could be
expanded with additional modeling and also data from future
analyses. Work is ongoing to build an accessory tool to classify
SMA into types akin to Srivivasta et al. by using machine learning
and other models [76]. Such a tool could be used in trials or
clinical practice to track a patient’s ‘type’ over time to assess
whether they are transitioning towards a more severe or mild
phenotype.
In summary, the SMA-MAP is the culmination of a biomarker
discovery campaign testing nearly 1000 plasma proteins, performed in multiple patient sample sets and quantitation technologies, and is ready for further validation to determine the extent of
its utility in clinical research and trials. Ongoing and future work
includes testing the panel with samples and data from interventional studies as well as in new longitudinal SMA natural history
studies, such as the one proposed for SMA in the NeuroNEXT
initiative [77]. Determining whether some SMA-MAP markers are
both motor function and PD markers remains an important next
step. This exploration will proceed in SMA animal models, and
also hopefully in new drug trials. The tool and its motor prediction
algorithm offer quantitative and objective evaluations that may
become valuable additions to the SMA clinical research community.

Johns Hopkins Medical Institutional Review Board; Mayo Clinic
Institutional Review Board; New England Research Institutes, Inc.
Institutional Review Board; The Ohio State University Biomedical
Institutional Review Board; Research Ethics Board for The
Hospital for Sick Children; Stanford University Institutional
Review Board; University of Alabama at Birmingham Institutional
Review Board for Human Use; University of Iowa Institutional
Review Board; The University of Utah Institutional Review
Board; The University of Western Ontario Research Ethics Board
for Health Sciences Research; University of Wisconsin Health
Sciences Institutional Review Board; The UT Southwestern
Institutional Review Board; Washington University in St. Louis
Institutional Review Board; Wayne State University Institutional
Review Board, Human Investigation Committee). Written informed consent for participation was obtained from the legal
guardians of all subjects and assent for participation was obtained
directly from subjects whenever applicable. S for children over 7
years of age [26].
Data and samples from SMA patients in the natural history
study by the Pediatric Neuromuscular Clinical Research (PNCR)
Network were collected under the auspices of the protocols
approved by each site’s IRB: Columbia University, The Children’s
Hospital of Philadelphia and the University of Pennsylvania, and
Harvard University [15,22]. Written informed consent or verbal
assent was provided and recorded by PNCR staff on IRBapproved documents for all PNCR parents or participants in the
natural history study, which allows for subsequent analysis with
study data and materials upon approval by the PNCR Biorepository Committee. Materials and data from the PNCR NHS were
made available following approved of a written request to the
PNCR Biorepository managed by Dr. Wendy Chung at Columbia
University. All BforSMA and PNCR NHS data were de-identified
and analyzed anonymously.

Platforms, Study Plasma Samples and Data
Data were generated across multiple discovery campaigns and
platforms using samples from different SMA studies. The first
platform was a LC/MS iTRAQ with analysis performed by BG
Medicine. The second platform was comprised of multiplexed
immunoassays using the Luminex system. Analysis with the
DiscoveryMAP v1.0H and OncologyMAP v1.0H panels, as well
as a 126 analyte pilot panel (containing the top 35 motor regressor
analytes from the tested MAPs) and the 27 analyte SMA-MAP
were all performed by Myriad RBM on the Luminex platform. 8
new Luminex immunoassays were created for top analytes that
regressed to motor function in the LC/MS campaign, and are
included in both the 126 analyte pilot panel and the SMA-MAP.
CILP2 and ADAMTSL4 were initially chosen for new assays but
were discarded due to poor reagent availability and assay
performance. Samples from the PNCR natural history study were
analyzed in the 126 analyte pilot panel.
The BforSMA study was a multi-center, pilot study enrolling
130 subjects, aged 2 to 12 years from 18 academic pediatric
neuromuscular clinics [25,26]. Each subject was seen for a single
visit, during which an assessment of functional ability (Modified
Hammersmith Functional Motor Scale, MHFMS), pulmonary
status (forced vital capacity, FVC), and nutritional status was
performed. There was no therapeutic intervention. Three groups
of SMA patients and one cohort of control children were enrolled
according to the following classifications in the BforSMA study:
type I SMA (n = 17), type II SMA (n = 49), type III SMA (n = 42),
healthy control children (n = 22). 129 plasma samples were
collected from the SMA patients and matched control subjects.

Materials and Methods
Ethics Statement
Healthy control and SMA patient samples from the BforSMA
study were collected in accordance with protocols approved by a
central Institutional Review Board (IRB) (New England Research
Institutes, Inc. Institutional Review Board) as well as by each sites’
IRB before enrollment at that site (Children’s Hospital of Boston
Institutional Review Board, Office of Clinical Investigation; The
Children’s Hospital of Philadelphia Institutional Review Board;
Cincinnati Children’s Hospital Medical Center Institutional
Review Board; Colorado Multiple Institutional Review Board University of Colorado Denver Institutional Review Board;
Columbia University Medical Center Institutional Review Board;
PLOS ONE | www.plosone.org

12

April 2013 | Volume 8 | Issue 4 | e60113

SMA-MAP Plasma Protein Biomarker Panel

‘‘reporter’’ molecule. Finally, the multiplex is washed to remove
unbound detecting reagents. After washing, the mixture of
microspheres is analyzed using the Luminex 100TM instrument.
Each individual microsphere passing through the instrument’s
excitation beams is analyzed for its encoded unique fluorescence
signature and the amount of fluorescence generated in proportion
to the analyte. As the microsphere passes through a green diodepumped solid state laser (532 nm) and is identified by its signature,
a fluorescence ‘‘reporter’’ signal (580 nm) is generated in
proportion to bound analyte concentration.

The PNCR SMA natural history study (NHS) was conducted at
Columbia University, Boston Children’s Hospital and Children’s
Hospital of Philadelphia, with the Muscle Study Group at the
University of Rochester serving as the data coordinating center
[15,22]. This NHS study was a multisite, longitudinal prospective
study enrolling 101 patients aged 3 months to 45 years from three
academic pediatric neuromuscular clinics. Subjects were assessed
using multiple motor scales and tests (HFMS, Expanded-HFMS;
Gross Motor Function Measure, GMFM; Children’s Hospital of
Philadelphia Test of Strength, CHOP-TOSS). Secondary outcome measures included pulmonary status (forced vital capacity,
FVC), strength (myometry for elbow and knee flexion, MyoEF and
MyoKF; Myometry for knee extension, MyoKE), nerve/muscle
physiology (compound motor action potential, CMAP and Motor
unit number estimation, MUNE) and quality of life (PedsQLTM
Parent and child scores). SMN1 and SMN2 were genotyped. Age
of onset and highest motor function were also collected by parental
or self-report. There was no therapeutic intervention. The 158
plasma samples for the pilot biomarker panel analysis included
three SMA groups from the 0 and 12 month NHS visits: subjects
with type 1 SMA (n = 27), type 2 SMA (n = 40) or type 3 SMA
(n = 34). N = 55 subjects were represented at both timepoints
(N = 9 type 1, N = 23 Type 2, and N = 23 type 3). PNCR patients
in the biomarker analysis ranged in age from 0.25 to 45.1 years.

SMA-MAP Validation Testing
The least detectable dose (LDD) was determined by adding
three standard deviations to the average of the signal for 20
replicate determinations of the standard curve blank. This value
was converted to concentration as interpolated from the standard
curve (LDD) and multiplied by the dilution factor used for testing
plasma samples. The lower limit of quantification (LLOQ) was
defined as the point at which the Coefficient of Variation (CV) for
samples was 30%. It was determined by 2 fold dilutions of
Standard 5 for 8 dilutions and assaying the samples in triplicate
over three different runs. The CV was calculated and plotted
against concentration. The LLOQ was interpolated from this plot,
multiplied by the dilution factor. The dynamic range is the range
of standard used to produce the dose response curve multiplied by
the dilution factor. Precision (Intra- and Inter-Run) was determined by measuring 3 levels of controls (C1–C3) in triplicate over
5 runs and provides information concerning random error
expected in a test result caused by person, instrument, and day
variations. The acceptance criteria for precision is C1,25% and
C2, and C3,20%. Acceptance criterion for most other metrics is
an average value between 70–130% (linearity, spike recovery,
interference, freeze-thaw, etc).
Cross-reactivity was determined by testing high concentrations
of each single standard in the multiplex assay. Linearity is the
ability of the assay to obtain test results that are proportional to the
concentration of analyte in the sample when serially diluted to
produce values within the dynamic range of the assay. Linearity
was determined by normal human plasma and control level 3
serially diluted in sample dilution buffer throughout the assay
range. The % recovery was calculated as observed vs. expected
concentration.
Spike recovery is used to account for interference caused by
compounds introduced from the physical composition of the
sample or sample matrix that may affect the accurate measurement of the analyte. Spike recovery was performed by spiking
different amounts of standard into the standard curve diluent
(control spike) and known serum and plasma samples. The average
% recovery was calculated as the proportion of spiked standard in
the sample (observed) to that of the control spike (expected). The
acceptance criteria for spike recovery are between 70–130% for a
minimum of 3 out of 6 samples. The purpose of matrix
interference is to determine whether the presence of substances
commonly found in samples that may interfere with immunoassays
introduce any systematic error in the multiplex. Matrix interference was determined by spiking Hemoglobin, Bilirubin, and
Triglyceride into samples and determining % recovery as observed
(spiked sample) vs. expected (unspiked sample). The purpose is to
determine the ability of an antigen to tolerate freeze-thaw cycles.
% Recovery is calculated by comparing the value of the treated
sample to the freshly thawed control sample multiplied by 100. For
some analytes, Plasma 3 and Serum 3 were spiked with
recombinant standard. Samples reported as ,LOW. are below
the LLOQ. Antigen stability was determined by leaving samples at

Liquid Chromatography
We performed a statistical reanalysis of the data previously
published by Finkel et al. in the BforSMA proteomics study; the
authors previously generated their results using a mass-spec/massspec (MS/MS) combined with iTRAQ labeling [26]. Briefly, the
plasma samples from the BforSMA study were depleted of high
abundance proteins sequentially by using an IgY14 column and a
supermix column (both by Sigma-Aldrich, St. Louis, MO).
Samples were reduced (TCEP), alkylated (iodoacetate) and
digested (trypsin) prior to 8-plex iTRAQ labeling. 6 of the 8plex channels were used for primary individually tagged samples
while the remaining 2 were a reference mixture pool of all
BforSMA samples. The labeled samples were pooled and
separated to 6 fractions using a strong cation exchange column.
Fractions were further processed by high pressure liquid chromatography (HPLC), matrix-assisted laser desorption/ionization
(MALDI), and MS/MS. The quantity of each protein analyte
was represented by an average ratio of reporter ion intensities
between the 6 primary sample channels and the 2 reference
channels. Signal integration, analysis and normalization was done
as described [26].

Immunoassay Multi-Analyte Profile (MAP)
Multiplexing was accomplished by assigning each analytespecific assay a microsphere set labeled with a unique fluorescence
signature. Each set of microspheres are encoded with a fluorescent
signature by impregnating the microspheres with a unique dye
combination. After encoding, an assay-specific capture reagent is
conjugated covalently to each unique set of microspheres, creating
an ELISA-like assay on each bead surface. After optimizing the
parameters of each assay separately, Multi-Analyte Profiles
(MAPs) are performed by mixing up to 100 different sets of the
microspheres in a single well of a 96- or 384-format microtiter
plate. A small sample volume of plasma (10 uL–20 uL) is added to
the well and allowed to react with the microspheres. The assayspecific capture reagent on each individual microsphere binds the
analyte of interest. A cocktail of assay specific, biotinylated
detecting reagents (e.g., antibodies), is reacted with the microsphere mixture, followed by a streptavidin-labeled fluorescent
PLOS ONE | www.plosone.org
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Table S3 Validation results for the SMA-MAP panel.
Assays for CD93, ENG, ERBB2, and IGF1 had minor issues with
cross-reactivity or dilutional linearity that are ameliorated with
dilution modification still within assay dynamic ranges. CLEC3B
measurements were imprecise when analyte levels were close to
the lower limit of quantitation. CLEC3B spike recovery could be
reduced due to the antibodies binding both monomeric and
tetrameric forms in the matrix while using a monomeric assay
standard. Plasma samples for CCL2, CLEC3B, and ERBB2 were
unstable at room temperature for .4 hours. Matrix interference
measures were conducted with spikes of up to 500mg/dL
hemoglobin or triglyceride, or 20 mg/dL bilirubin. Dilutions
tested were 1:10, 1:20, and 1:40. Freeze thaw values shown are
from the third freeze thaw cycle. Antigen stability range represents
the signal present with sample storage for 2 h at 4uC to 24 h at
room temperature. *Indicates that there was 20% interference
when COMP is present with THBS4; the analytes are known to
bind in vivo.
(DOCX)

room temperature and 4uC for the times listed below. % Recovery
is calculated by comparing the value of the treated sample to the
freshly thawed control sample multiplied by 100. For some
analytes, Plasma 3 and Serum 3 were spiked with recombinant
standard.

Statistical Methods
All analyses were performed using R version 2.12 or higher.
Analytes that had a high number of missing values (e.g. greater
than 40% of the samples had values below limits of detection) were
excluded from the analyses. P-values graphically depicted are
indicated by asterisks or plus signs in the following manner:
p,0.001 by ***, p,0.01 by ** and p,0.05 by *.
In the discovery phase, candidate biomarkers were identified
based on their association with Hammersmith score and other
clinical outcomes in both univariate and multivariate analyses
including ANOVA, t-test and Pearson correlation and by
multivariate regression analysis (linear, lasso, random forest).
Default values of the R functions were used for model tuning
parameters (such as lambda for lasso and mtry for random forest).
These analyses examined biomarker associations with multiple
dependent variables: MHFMS scores, SMN2 copy number, SMN
protein levels, and quantity of SMN2 full length, SMN-full length,
SMN delta7, and total SMN transcripts. Analytes with significant
association with one or more clinical variables in the discovery
phase were candidates for inclusion in the validation phase, subject
to non-statistical criteria such as assay performance, known
biological relationships, and frequency of values at or near the
lower limits of quantification or detection.
Univariate analysis in the validation phase identified 13 analytes
as the best predictors. Because motor scale values are censored at 0
and 40, we implemented Tobit regression models to predict motor
function scores [27]. We examined subsets of the 13 using best
subsets analysis. All 13 analytes were entered as candidates in the
models. Performance of the models was compared using adjusted
R2 values calculated on bootstrap (out-of-bag) samples. Two Tobit
models are reported; one using the 13 selected analytes (data not
shown) and one using the 6 analytes in the best subset resulting
from the best subsets analysis. MHFMS scores are bounded by
floor (0) and ceiling (40) values, so we also examined Tobit models
excluding these extremes. Excluding 0 and 40 MHFMS scores
reduced the analytes’ predictive power, so this was not pursued.

Table S4 Adjusted R2 of the top 13 analytes predicted
SMA motor and non-motor outcomes to actual patient
values using the PNCR NHS. The adjusted R2 values were
based on the linear regression to predicted outcome measures
using the 13 motor analytes with and without age of onset as a
clinical covariate. Predictive ability is similar among the motor
scales, and correlation values are generally greater for the motor
scales than the non-motor outcomes with the exception of
pulmonary function (FVC).
(DOCX)
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